SUN PHARMA France SAS Vear ended 31 March 2020

Statutory auditor's report on the annual financial statements

To the shareholders of Ranbaxy Pharmacie Génériques SAS,

Opinion

In compliance with the engagement entrusted to us by your Annual General Meeting of Shareholders, we have audited the accompanying financial statements of SunPharma France for the year ended 31 March 2020, as attached to this report. These annual accounts were adopted by the President on 15 May 2020 on the basis of the information available at that time date in the evolving context of the Covid-19 health crisis.

In our opinion, the annual financial statements give a true and fair view of the results of the Company's operations for the year then ended and of the financial position and the assets and liabilities of the Company as at 31 March 2020, in accordance with the accounting rules and principles applicable in France.

Basis for opinion

Audit Framework

We conducted our audit in accordance with professional standards applicable in France. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under those standards are further described in the "Statutory Auditors' Responsibilities for the Audit of the Financial Statements" section of our report.

Independence

We conducted our audit in compliance with independence rules applicable to us, for the period from 1 April 2019 to the issue date of our report and we did not provide any services prohibited by the French Code of Ethics for statutory auditors.

Observation

Without qualifying the above opinion, we would bring your attention to the note to the financial statements entitled Accounting Rules and Methods – Shareholders' Equity indicating that the company received financial support from its parent up to 31 March 2021.

Justification of assessments

In accordance with the requirements of articles L.823-9 and R.823-7 of the French Commercial Code (*Code de commerce*) relating to the justification of our assessments, we hereby inform you that the key audit matters we addressed as being, in our professional judgment, of most significance in the audit of the financial statements of the current period, related to the appropriate nature of the accounting principles applied.

These assessments were arrived at in the context of our audit of the financial statements as a whole, and in forming our opinion thereon. We do not provide a separate opinion on specific elements of the financial statements taken in isolation.

Specific verifications

We have also performed, in accordance with professional standards applicable in France, the specific verifications required by French law and regulations.

We have no matters to report as to the fair presentation and the consistency with the financial statements of the information given in the Chairman's report of the Board of Directors and in the other documents provided to shareholders with respect to the financial position and the financial statements.

We attest to the fair presentation and consistency with the annual financial statements of the information on payment terms referred to in article D.441-4 of the French Commercial Code.

Responsibilities of management and those charged with governance for the annual financial statements

Management is responsible for the preparation and fair presentation of the annual financial statements in accordance with French accounting principles, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless it is expected that the Company will be liquidated or will cease its operations.

The financial statements have been approved by the Chairman of the Board of Directors.

Statutory auditor's responsibilities for the audit of the annual financial statements

Our role is to issue a report on the annual financial statements. Our objective is to obtain reasonable assurance about whether the annual financial statements as a whole are free from material misstatement. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with professional standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As specified in Article L. 823-10-1 of the French Commercial Code, our statutory audit does not include assurance on the viability of the Company or the quality of management of the affairs of the Company.

As part of an audit conducted in accordance with professional standards applicable in France, the statutory auditor exercises professional judgment throughout the audit and furthermore:

- identifies and assesses the risks of material misstatement in the annual financial statements, whether due to fraud or error, designs and performs audit procedures responsive to those risks, and obtains audit evidence considered to be sufficient and appropriate to provide a basis for his opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- obtains an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control;

- evaluates the appropriateness of accounting methods used and the reasonableness of accounting estimates and related disclosures made by management in the financial statements;
- assesses the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. This assessment is based on the audit evidence obtained up to the date of the audit report. However, future events or conditions may cause the Company to cease to continue as a going concern. If the statutory auditor concludes that a material uncertainty exists, there is a requirement to draw attention in the audit report to the related disclosures in the annual financial statements or, if such disclosures are not provided or are not pertinent, to modify the opinion expressed therein;
- evaluates the overall presentation of the annual financial statements and whether these financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

11 May 2020 BDO Paris Audit & Advisory Represented by Eric Picarle, Statutory Auditor

[Translated from the French]

Table of Contents

SUN PHARMA FRANCE

From 01/04/2019 to 31/03/2020

Statement	1
FINANCIAL STATEMENTS	2
Balance sheet assets	3
Balance sheet Liabilities	4
Income statement	5
DETAILS OF FINANCIAL STATEMENTS	6
Details of Assets	7
Details of Liabilities	9
Details of the Profit and Loss Statement	11
	15
Accounting rules and methods for SMEs	16
Fixed Assets	21
Depreciation and amortisation	22
Provisions	23
Payables and Receivables	24
Accrued income	25
Accrued expensed	26
Prepayments	27
Prepaid income	28
Breakdown of turnover	28
Capital social	29
Breakdown of turnover	30
Breakdown of tax on profits	31
Increase and decrease in future tax liabilities	32
Directors and senior managers' remunerations	33
Average headcount	34
Consolidating parent companies	35
Subsidiaries and associates 1	36
TAY FORMS	37

:

Statement of presentation of accounts

Statement expressed in Euros

In connection with the assignment relating to the Presentation of the annual financial statements of SUN PHARMA FRANCE, for the period covering 01/04/2019 to 31/03/2020, and in accordance with the terms of reference of our engagement letter and our agreements, we, the Chartered Accountancy firm SOGECC, have carried out the checks as defined by the Institute of Chartered Accountants.

The Annual Financial Statements enclosed show the following:

Balance sheet total: 13,551,356 Euros

Turnover: **27,042,241** Euros

Net income: -2,991,334 Euros

SOGECC SUN PHARMA FRANCE Page:

FINANCIAL
STATEMENTS TO
31/03/2020

Balance sheet assets

	Ī		31/03/2019		
Statement expressed in Euros		Gross	Amort. and Deprec.	Net	Net
	Capital subscribed uncalled (I)				
	INTANGIBLE ASSETS Preliminary costs Development costs Licences, patents and similar rights Goodwill (1) Other intangible assets Advances and prepayments	12,251,753	12,243,411	8,342	25,549
FIXED ASSETS	TANGIBLE ASSETS Land Buildings Technical installations, indus. equip. &. tools Other tangible assets Fixed assets in progress Advances and prepayments	289,464	150,332	139,132	165,559
	FINANCIAL ASSETS (2) Investments in associates valued by the equity method. Other equity interests Receivables from associates	4,372,238	3,372,238	1,000,000	1,000,000
	Other fixed investments Loans Other financial assets	68,385 40,111	68,385	40,111	40,111
	TOTAL (II)	17,021,950	15,834,365	1,187,585	1,231,219
SETS	STOCK AND WORK IN PROGRESS Raw materials & supplies Work in progress for production of goods Work in progress for production of services Intermediate and finished products Goods	155,713	7,012	148,701	88,722
ASS	Advances and Prepayments paid on orders	6,141,010	1,939,650	4,201,360	5,502,035
CURRENT AS	RECEIVABLES (3) Trade receivables and related accounts Other receivables Capital subscribed and called up, unpaid	279,774 5,485,555 731,281	328,735	279,774 5,156,819 731,281	71,291 4,194,047 659,838
	MARKETABLE SECURITIES				
	CASH IN HAND/AT BANK	1,482,459		1,482,459	2,835,903
	Prepayments	363,376		363,376	321,148
IALS	TOTAL (III)	14,639,168	2,275,397	12,363,771	13,672,983
ACCRUALS	Loan issuance cost to be spread (IV) Premiums on the redemption of debentures (V) Unrealised exchange difference (VI)				
	TOTAL ASSETS (I to VI)	31,661,118	18,109,762	13,551,356	14,904,203
	(1) including leasehold right(2) including financial assets of less than one year(3) including receivables of more than one year			336,397	354,848

ge:

Balance sheet liabilities

	Statement expressed in Euros	31/03/2020	31/03/2019
	Total share capital Issue, merger, acquisition and such premiums Differences arising on revaluation	24,948,400	24,948,400
Capital and Reserves	RESERVES Legal reserve	726,132 167,958	726,132 167,958
d Re	Statutory or contractual reserves Regulated reserves	1,282,809	1,282,809
al an	Other reserves	(59,165,485)	(54,454,963)
apit:	Balance brought forward	(2,991,334)	(4,710,522)
\bigcap	Profit/loss for the year		
	Investment subsidies Regulated provisions		
	Total capital and reserves	(35,031,519)	(32,040,186)
Other capital and reserves	Income from issues of participating shares Conditional advances		
Oth	Total other capital and reserves		
Provisions	Provisions for risks Provisions for charges	209,416 290,215	123,000 250,835
Pre	Total provisions	499,631	373,835
	FINANCIAL DEBTS		
PAYABLES (1)	Convertible debenture loans Other debenture loans Loans and debts from credit institutions (2) Other loans and financial debts Advances and prepayments received on orders in progress	16,592 34,616,561	4,000 35,293,115
PA	OPERATING DEBTS		
	Trade payables and related accounts Tax and social security liabilities	11,501,681 1,941,516	9,449,285 1,055,019
	OTHER PAYABLES		
	Payables on fixed assets and related accounts Other payables	6,895	769,135
	Prepaid income (1)		
	Total payables	48,083,245	46,570,553
	Unrealised exchange losses		
	TOTAL LIABILITIES	13,551,356	14,904,203
(1		(2,991,333.52) 48,083,245	(4,710,521.73) 46,570,553
(2) Of which bank facilities and overdrafts, bank credit balance and PCA	16,592	4,000

Income statement		31/03/2020		31/03/2019	
		12 months	% C.A.	12 months	% C.A.
	Sale of goods	25,848,830	95.59	22,000,480	100.00
OPERATING INCOME	Production sold (Goods) Production sold (Services and Works)	1,193,412	4.41	133	
OPERAT INCOME	Net turnover	27,042,241	100.00	22,000,613	100.0
OF	Production for stock Capitalised production costs Operating subsidies Reversals on provisions and depreciation, transfer of charges Other income	1,073,465 285		375,508 12,128	1.77 6.00
	Total operating income	28,115,992	103.97	22,388,248	101.70
OPERATING EXPENSES	Purchase of goods Variations in stock Purchases of raw materials and other supplies Variations in stock Other external purchases and expenses	12,578,545 122,766 407,960 (38,302) 12,337,423	46.51 0.45 1.51 - 0.14 45.62	14,600,437 (2,933,175) 297,827 135,584 10,286,585	66.36 -13.33 1.35 0.62 46.76
NG	Taxes, duties and similar payments Wages and salaries	882,017 1,739,257	3.26	832,895 1,629,846	3.79 7.41
PERATI	Personnel social security charges Owner's personal contributions to social security	808,609	6.43 2.99 9.05	692,404	3.15
	Amortisation, depreciations and provisions Other expenses	2,448,030 58,375	0.22	1,112,257 135,205	0.6
	Total operating expenses	31,344,680	115.91	26,789,865	121.7
	OPERATING PROFIT/LOSS	(3,228,688)	-11.94	(4,401,617)	-20.01
FINANCIAL Opera. INCOME comm.	Profit appropriated or loss transferred Loss borne or profit transferred From equity interests (3) From other marketable securities and fixed asset receivables (3) Other interests and similar income (3) Reversal of provisions and depreciation and transfer of charges Exchange gains Net income from the sale of investment securities	1,245		73	
	Total financial income	1,245		73	
FINANCIAL	Amortisation, depreciation and provisions Interests and similar expenses (4) Exchange losses Net expenses from the sale of investments securities	531,433 932	1.97	527,166 5,903	0.03
3	Total financial expenses	532,365	1.97	533,069	2.42
	FINANCIAL PROFIT/LOSS PROFIT/LOSS BEFORE TAX	(531,120) (3,759,808)	-1.96 -13.90	(532,996) (4,934,613)	-2.42 -22.43
	Total extraordinary income Total extraordinary expenses	796,868 28,393	2.92 0.10	224,442 350	1.02
	EXTRAORDINARY PROFIT/LOSS EMPLOYEE PROFIT-SHARING TAX ON PROFITS	768,475	2.84	224,091	1.02
	TOTAL INCOME TOTAL EXPENSES	28,914,104 31,905,438	106.92 117.98	22,612,763 27,323,285	102.78 124,.19
	PROFIT/LOSS FOR THE YEAR	(2,991,334)	-11.06	(4,710,522)	-21.4

SOGECC SUN PHARI

SUN PHARMA FRANCE

Page:

DETAILS OF FINANCIAL STATEMENTS TO 31/03/2020 SOGECC SUN PHARMA FRANCE

Details of the Assets

Page:

Report expressed in Euros	01/04/2019 12 31/03/2020 mos	nths	01/04/2018 12 31/03/2019 months	Variations %
Uncalled subscribed capital				
TOTAL II – NET fixed assets	1,187,585.33	8.76	1,231,219.26 8.26	(43,633.93) -3.54
Concessions. patents and similar rights	8,342.29	0.06	25,548.89 <i>0.17</i>	(17,206.60) -67.35
20510660 Computer equipment 20520660 PATENTS 20530662 LICENSES (excluding AA)	24,629.89 449,725.60 180,286.21	0.18 3.32 1.33	24,629.89 0.17 449,725.60 3.02 180,286.21 1.21	
20540660 TRADEMARKS 29050660 Provisional Intangible Assets 29050662 PROV LICENSE DEPRECIATION 28050660 Compter equip. depreciation	11,597,111.24 (266,532.00) (180,286.21) (20,347.60)	85.58 -1.97 -1.33 -0.15	11,597,111.24 77.81 (266,532.00) -1.79 (180,286.21) -1.21 (12,453.00) -0.08	(7,894.60) -63.40
28052660 PATENTS AMORT 28054660 TRADEMARKS AMORT	(449,725.60) (11,326,519.24)	-3.32 -83.58	(449,725.60) - ^{3.02} (11,317,207.24) - ^{75.93}	(9,312.00) -0.08
Other tangible fixed assets	139,131.78	1.03	165,559.11 1.11	(26,427.33) -15.96
21820000 Transport equipment 21830500 OFFICE EQUIPMENT - OPERATIONS 21830600 IT HARDWARE 21840000 Furnishings & Installations. Agenc 28183500 DEPREC OFFICE HARDWARE-EXPL 28183600 DEPREC IT HARDWARE 28183700 Vehicles other than Buses & Lo 28184000 Amortisation- Mob & Installat	19,577.23 16,916.33 73,477.02 179,493.00 (15,700.80) (68,489.00) (7,504.00) (58,638.00)	0.13 0.11 0.54 1.32 -0.12 -0.51 -0.00 -0.43	19,577.23 0.13 16,916.33 0.11 63,262.00 0.42 179,493.00 1.20 (13,879.80) -0.09 (55,532.65) -0.37 (3,589.00) -0.02 (40,688.00) -0.27	$ \begin{array}{r} 10,215.02 16.15 \\ (1,821.00) -13.12 \\ (12,956.35) -23.33 \\ (3,915.00) -109.08 \\ (17.050.00) 44.13 \\ \end{array} $
Other holdings	1,000,000.00	7.38		(17,950.00) -44.12
26110101 GROUP EQUITY SECURITIES 29611010 Provision Share investments	4,372,238.01 (3,372,238.01)	32.26 -24.88	1,000,000.00 6.71 4,372,238.01 ^{29.34} (3,372,238.01) - ^{22.63}	
Loans 27430130 LOANS FOR THE CONSTRUCTION EFFORT 29743013 Provision Loans – Const efforts	68,384.68 (68,384.68)	0.50 -0.50	68,384.68 0.46 (68,384.68) -0.46	
Other financial fixed assets	40,111.26	0.30	40,111.26 0.27	
27510200 DEPOSITS AND SURETY BONDS PAID	40,111.26	0.30	40,111.26 0.27	
TOTAL III – NET current assets	12,363,770.99	91.24	13,672,983.34 91.74	(1,309,212.35) -9.58
Unprocessed materials, supplies	148,700.91	1.10	88,721.83 0.60	59,979.08 67.66
31100100 STOCKS API RAW MATERIALS - 32600603 STOCKS DPO PACKAGING ARTICLES 39110100 PROV DEPR.STOCKS API MATERIALS	144,222.69 11,490.44 (7,012.22)	1.06 0.08 -0.05	88,606.92 0.59 7,127.13 0.05 (7,012.22) -0.05	55,615.77 62.77 4,363.31 61.22
Merchandise	4,201,360.38	31.00	5,502,035.10 36.92	(1,300,674.72)-23.64
37200510 MERCHANDISE DPO STOCKS 37210000 In-transit inventories 39720510 PROV DEPR.STOCKS DPO MARCHANDI	6,132,071.57 8,938.38 (1,939,649.57)	45.25 0.07 -14.31	6,227,927.83 <i>41.79</i> (725,892.73) <i>-4.87</i>	(95,856.26) -1.54 8,938.38
Advances & instalments paid on orders	279,774.42	2.06	71,291.13 0.48	(1,213,756.84) -167.21 208,483.29 292.44
40910300 CGS A-AVANCE & ACPT/B&S-FRS TI	279,774.42	2.06	71,291.13 0.48	208,483.29 ^{292.44}
Trade receivables and related accounts	5,156,819.46	38.05	4,194,046.57 28.14	962,772.89 22.96
41110100 COLLECTIVE THIRD PARTY CUSTOMERS (PRODUCT) 41600000 Doubtful customers 41800000 TRADE RECEIVABLES, UNBILLED REVE	5,019,464.43 336,396.56 129,693.65	37.04 2.38 0.96	4,186,770.63 28.09 354,848.30 2.38 (347,572.36) -2.33	832,693.80 19.89 (18,451.74) -5.20 129,693.65 18,837.18 5.42
49110100 PROV DEPRECIAT°CUSTOMER RECEIVABLE Other receivables 40971760 Reclassif. outstanding suppliers	731,281.01 4,461.46	-2.43 5.40 0,03	659,837.68 4.43 4,461.46 0.03	71,443.33 10.83

8

Details of the Assets

		01/04/2019 12		01/04/2018 12		
	Report expressed in Euros	31/03/2020 mo	nths	31/03/2019 mo	onths	Variations %
42500230	PERSONNEL-SALARY ADVANCES	1,500.00	0.01	1,500.00	0.01	
42510200	EXPENSE ACCOUNTS	2,526.64	0.02	'		2,526.64
42541130	PERMANENT ADVANCES (PAYROLL)	5,500.00	0.04		0.02	500.00 10.00
42700140	ADVANCES ON OBJECTIONS	5,629.00	0.04	5,000.00	0.03	5,629.00
43111200	SOCIAL SECURITY – DAILY BENEFITS	20,076.87	0.15	14 674 40	0.10	5,422.39 37.00
43710110	MEAL VOUCHERS	31,977.16	0.13	14,654.48	0.10	9,768.11 43.98
43750131	ADVANCED PROVIDENT FUND	1,412.83	0.01	22,209.05	0.13	1,412.83
43/30131	BENEFITS	1,412.03	0.01	0.06		$(0.06)^{-100.00}$
43864250	APPRENTICESHIP TAX		i	0.00		6,030.38
44410670	GOVTINCOME TAX INTERIM PAYMENT	6,030.38	0.04	134,226.05	0.90	414,083.87 308.50
44566010	VAT DEDUCTIBLE/RECEIPTS-A	548,309.92	4.05	280.17		33,861.54 N/S
44566120	VAT DEDUCTIBLE ON DEBITS	34,141.71	0.25		0.02	27,568.20 N/S
44566140	DEDUCTIBLE EU VAT ON DEBITS	29,814.33	0.22	2,246.13	0.02	(189.97) -44.52
44566680	RECUP VAT THE REPORT OF THE EU O	236.71		426.68	2.86	$(426,391.60)^{-100.00}$
44583670	REQUESTED VAT REIMBURSEMENTS			426,391.60		(8,778.00) -18.12
44870300	REPORT – ACCRUED REVENUES	39,664.00	0.29	48,442.00	0.33	
				2,835,903.45	19.03	(1,353,444.26) -47.73
Cash on hand		1,482,459.19	10.94	171,794.79	1.15	(143,676.52) -83.63
51210000	Crédit Lyonnais	28.118.27	0.21	20,564.14	0.14	$(640.55)^{-3.11}$
51260000	Crédit FR87 30002007980000403	19,923.59	0.15	2,058,902.35	13.81	$(2,058,902.35)^{100.00}$
51280000	HSBC - France-mainland	,		584,545.45	3.92	849,795.16 -145.38
51280100	HSBC - CSP	1,434,340.61	10.58	96.72		(20.00) -20.68
53110000	CASH IN EUROS	76.72		90.72		
Deferred expe	nses	363,375.62	2.68	321,147.58	2.15	42,228.04 13.15
48600101	DEFERRED EXPENSES-AS	3,482.42	0.03	5,217.99	0.04	(1,735.57) -33.26
48600300	DEFERRED EXPENSES-AU	359.893.20	2.66	315,929.59	2.12	43.963.61 13.92
1000000	DEI ERRED ERI ELIGEO NO	337,873.20		313,727.37		45,705.01
BALANCE SH	HEET ASSETS TOTAL	13,551,356.32	100.00	14,904,202.60	100.00	(1,352,846.28) -9.08

SOGECC

SUN PHARMA FRANCE

Page:

Details of the Liabilities

	Report expressed in Euros	01/04/2019 12 31/03/2020 mc	onths
TOTAL I – Sh	nareholders equity	(35,031,519.39)	-258.5
Corporate or	individual capital	24,948,400.00	184.10
10130100	SUBSCRIBED CAPITAL CALLED PAID	24,948,400.00	184.10
Legal reserve		726,132.00	5.36
10611100	LEGAL RESERVE	726,132.00	5.36
Statutory or co	ontractual reserves	167,957.78	1.24
10630120	STATUTORY OR CONTRACTUAL RESERVES	167,957.78	1,24
Other Reserve	es	1,282,808.87	9.47
10680300	OTHER SPECIAL RESERVES	1,282,808.87	9.47
Retained earn	ings	(59,165,484.52)	-436.6
11000100	RETAINED EARNINGS	(59,165,484.52)	-436.6
FINANCIAL	YEAR RESULTS	(2,991,333.52)	-22.07

01/04/2018 12 31/03/2019 months
(32,040,185.91)-214.9
24,948,400.00 203.51
24,948,400.00 ^{203.51}
726,132.00 4.87
726,132.00 4.87
167,957.78 1.13
167,957.78 ^{1.13}
1,282,808.87 8.61
1,282,808.87 8.61
(54,454,962.83) -365.3
(54,454,962.83) -365.3
(4,710,521.73) -31.61

Variations	%
(2,991,333.48)	9.34
(4,710,521.69)	-8.65
(4,710.521.69)	-8.65
1,719,188.21	36.50
L	

TOTAL II – (Other shareholders equity		
TOTAL III - 7	Fotal provisions	499,631.10	3.69
Provisions for	contingencies	209,416.00	1.55
15110100	PROV FOR LITIGATION	198,416.00	1.46
15180000	Other Provision for Contingencies & Charges	11,000.00	0.08
Provisions for	losses	290,215.10	2.14
15311120	PROV RETIREMENT BENEFITS	290,215.10	2.14

373,835.10	2.51
123,000.00	0.83
123,000.00	0.83
250,835.10	1.68
250,835.10	1.68

125,796.00	33.65
86,416.00	70.26
75,416.00 11,000.00	61.31
39,380.00	15.70
39,380.00	15.70

TOTAL IV -	Total debts	48,083,244.61 354.82
Loans & rece	ivables with credit institutions	16,591.66 0.12
51280000	HSBC - France-main	12,591.66 0.09
51810000	PAYABLE ACCRUED INTEREST	4,000.00 0.03
Miscellaneous	s financial loans and debts	34,616,560.74 255.45
16810000	LOANS FROM THE GROUP	32,102,185.00 236.89
16888000	INTEREST ON GROUP LOANS	959,876.18 ^{7.08}
45100410	OPIH current account	1,554,499.56 <i>11.47</i>
Trade credito	ors and other accounts payable	11,501,681.21 84.87
40100100	THIRD PARTIES – SUPPLIERS COLLECTIVE	792,100.25 ^{5.85}
40200100	GROUP-SUPPLIERS COLLECTIVE	9,528,580.03 70.31
40810000	INV NOT RECEIVED ACCT Entry M	565,782.79 ^{4.18}
40810502	SUPPLIER INV NOT RECEIVED	615,218.14 <i>4.54</i>
Tax and socia	ll security liabilities	1,941,516.00 14.33
42110110	STAFF REMUNERATION	2,693.48 0.02
42200100	EC SUBSIDIARIES FOR FUNCTIONING	815.21 0.01
42200110	EC SUBSIDIARIES SOCIAL ACTIONS	3,665.99 0.03
42200110 42510200	EC SUBSIDIARIES SOCIAL ACTIONS Financial participation withholding	3,665.99 0.03
		3,665.99 0.03 11,474.61 0.08
42510200	Financial participation withholding	3,003.77
42510200 42820140	Financial participation withholding TOIL PROVISIONS	11,474.61 0.08 45,663.38 0.34 120,638.27 0.89
42510200 42820140 42820150	Financial participation withholding TOIL PROVISIONS PROVISIONS HOLIDAYS TO BE PAID	11,474.61 0.08 45,663.38 0.34 120,638.27 0.89 14,069.89 0.10
42510200 42820140 42820150 42820160	Financial participation withholding TOIL PROVISIONS PROVISIONS HOLIDAYS TO BE PAID PROVISIONS FOR HOLIDAYS TO BE PAID	11,474.61 0.08 45,663.38 0.34 120,638.27 0.89

46,570,553.41 312.47
4,000.00 0.03
,
4,000.00 0.03
4,000.00
35,293,144.88 236.80
32,102,185.00 215.39
590,929.88 ^{3.96}
2,600,000.00 17.44
9,449,285.09 63.40
614,631.53 4.12
8,386,307.60 56.27
159,858.71 1.07
288,487.25
200,707.23
1,055,018.88 7.08
1,228.30 0.01
750.78 0.01
3,378.52 0.02
10,271.64 0.07
7,696.97 0.05
44,870.27 0.30
118,324.35 0.79
13,696.74 0.09
276,065.31 <i>1.85</i>
55,750.58 0.37
,

1,512,691.20 ^{3.25}
12,591.66 314.97
12,591.66
(676,554.14) -1.92
368,946.30 62.45 (1,045,500.44)-40.21
2,052,396.12 21.72
177,468.72 ^{28.87} 1,142,272.43 ^{13.62} 405,924.08 ^{253.93} 326,730.89 ^{113.26}
886,497.12 84.03
1,464.18 119.20 64.43 8.58 287.47 8.51 (10,271.64) -100.00 3,777.6449.08 793.11 1.77 2,313.92 1.96 373.15 2.72 (19,293.10) -6.99 12,934.95 23.20

10

Details of the Liabilities

Report expressed in Euros

01/04/2019 12 31/03/2020 months 01/04/2018 12 31/03/2019 months 34,211.68 19,564.31 0.13 220.38 6,398.78 0.04 0.07 10,477.23 81,597.37 0.55 6,848.37 0.050.05 7,262.00 1,178.72 0.010.09 13,183.21 0.02 2,246.13 28,000.75 0.19 2.09 311,562.24 234.25 769,134.56 5.16 769,134.56 5.16

769 134,56 769 134,56

> 6,648.30 19.43 9 865,67 50.43 (6,052.45) -94.59 5,977.17 *57.05* 1,674.04 2.05 186.58 2.72 920.34 12.67 2,770.19 (1,178.72) -100.0 (515.98) -3.91 27,568.20 N/S 71,858.29 (22,684.75) -81.01 797,250.38 255.89 (234.25) -100.00 (762,239.56) -99.10

14,904,202.60 100.00

(1,352,846.28) -9.08

6,895.00 (769,134.56) .-100.00

BALANCE S	HEET LIABILITIES TOTAL	13,551,356.32 100.00
43710120	RETIREMENT INSTITUTIONS – OTHER	40,859.98 0.30
43720130	PROVIDENT FUND INSTITUTIONS – OTHER	29,429.98 0.22
43730140	ASSEDIC/GARP	220.38
43740150	Mutual insurance	346.33
43860220	SOCIAL CHARGES TO BE PAID	16,454.40 0.12
43860221	SOCIAL ORG. – CHARGES TO BE PAID	93,271.41 0.61
43860222	SOCIAL ORG. – CHARGES TO BE PAID	7,034.95 0.05
43863240	BUILDING INITIATIVE	8,182.34 0.06
43864250	APPRENTICESHIP TAXES.	2,770.19 0.02
43865270	PROFESSIONAL TRAINING	
44210000	TDS - Salaries	12,667.23 0.09
44520660	TVA DUE SUR ACQUISITIONS INTRA	29,814.33 0.22
44710660	REPORT – PROFESSIONAL TAX	71,858.29 0.53
44740110	REPORT – TAX PHARMAC. SPECIALITIES	5,316.00 ^{0.04}
44750120	TAXES ON DIRECT SALES	1,108,812.62 8.18
44760130	Tax on comp. cars	
Other debts		6,895.00 0.05
41980000	CUSTOMER CREDITS NOTES NOT YET ISSUED	6,895.00 0.05
46710220	CHEQUES NOT REMITTED FOR COLLECTION-	,

Report expressed in Euros	01/04/2019 12 31/03/2020 months	01/04/2018 12 31/03/2019 months	Variations %
Total operating income	18,901,858 103.97	22,388,428.19 101.76	5,727,743.48 25.58
Sales of merchandise	25,848,829.61 95.59	22,000,479,73 100.00	3,848,349.88 17.49
	· · ·		0,010,019100
Sales of merchandise FRANCE 70701710 FRANCE MERCHANDISE SALES HG	25,848,829.61 <i>95.59</i> 33,075,488.53 <i>122.31</i>	22,000,479.73 <i>100.00</i> 28,785,703.74 <i>130.84</i>	3,848,349.88 <i>17.49</i> 4,289,784.79 <i>14.90</i>
70701710 FRANCE MERCHANDISE SALES HG 70970000 REBATES. ALLOWANCES & DISCOUNTS GRANTED	(7,226,658.93) -26.72	6,785,224.01) -30.84	(441,434.91) -6.51
Sold production of goods			
Sold production Services + Works	1,193,411.82	133.33	1.193.278.49 N/S
Sold production Services FRANCE	26,356.47 0.36		
70620410 FRANCE MISCELLANEOUS SERVICES H	21,885.19	133.33	26 223 14 N/S
70880000 INCOME FROM RELATED ACTIVITIES	4,471.28	133.33	26,223,14 N/S
Sold production Services EXPORT 70695000 OTHER EXPORT SERVICES	1,167,055.35 <i>4.32</i> 1,167,055.35 <i>4.32</i>	155.55	1,167,055,35 1,167,055,35
Sales figure net amount	27,042,241.43 100.00	22,000,613.06 100.00	5,041,628.37 22.92
Reversals on deprec. & prov transfers of expenses	1,073,465.09 3.97	375,507.59 ^{1.71}	697,957.50 185.87
78173000 Rev. on provision for depre 78174000 BAD DEBTS PROV REF	725,892.73 2.68 347,572.36 1.29	152,044.41 0.69 223,463.18 1.02	573,848.32 377.42 124,109.18 55.54
Other operating income	285.15		(11.842.39) -97.65
75800000 MISCELLANEOUS OPERATING INCOME	285.15	12,127.54 0.06 12,127.54 0.06	(11,842.39) -97.65 (11,842.39) -97.65
Total operating expenses	31,344,679.56 115.91		
Merchandise purchases	12,578,544.75 46.51	26,789,865.00 121.77	4.554.814.5 17.00
60710580 PURCHASES MERCHANDISE STOCKS	12,164,669.59 44.98	14,600,436.85 66.36	(2,021,892.10) -13.85
60870000 Incidental expenses on purchase 60870110 CUSTOMS DUTIES & OTHER EXPENSES	413,626.31 <i>1.53</i> 248.85	14,114,263.61 _{64.15} 483,473.70 _{2.20}	(1,949,594.02) -13.81
		2,699.54 0.01	(69,847.39) -14.45 (2,450.69) -90.78
Variation of merchandise stocks	122,765.76 0.45		40.40
60370584 VARIATION OF MERCHANDISE STOCKS	122,765.76 0.45	(2,933,175.48) -13.33	3,055,941.24 104.19
Purchases of raw materials and other supp.	407,959.66 1.51	(2,933,175.48)	3,055,941.24
60100100 RAW MATERIALS STORED PURCHASES	407,959.66 1.51	297,826.52 1.35	110,133.14 36.98
Variation of procurement stocks	(38,3010) -0.14	297,826.52 ^{1.35}	110,133.14 36.98
60310101 VAR STOCKS RAW MATER incoming	(68,118.02) -0.25	135,584.12 0.62	(173,886.02) -128.25
60320621 VAR STOCKS PACKAGING INCOMING/A	29,816.12 0.11	95,471.94 0.43 40,112.18 0.18	(163,589.96) -171.35 (10,296.06) -25.67
Other external purchases and expenses	12,337,422.71 45.62	10,286,585.16 46.76	2,050,837.55 19.94

	Other externa	l purchases and expenses	12,337,422.71	45.62
	60500000	HA materials, equipment and	1,232.00	
İ	60610018	Vehicle fuel	2,152.62	0.01
İ	60612010	ELECTRICITY NON-STORED PURCHASES	8,412.26	0.05
İ	60633010	OTHER PETI NON-STORED PURCHASES	12,312.12	0.05
	60681000	SAMPLE NON-STORED PURCHASES	0.55	
	60940000	Rebates/discounts/allowances on purchases		
	61101115	GLOBAL SERVICE EXPENSE-COST A	4,528,107.20	16.74
İ	61102000	Provisions of Services.	681,058.00	2.52
İ	61103000	SUB-CONTRACT PAYROLL	30,812.44	0.11
	61103004	SUB-CONTRACT PAYROLL	26,698.89	0.10

10,286,585.16	46.76	
3,317.148	0.02	
9,772.56	0.04	
18,636.72	0.08	
18.94		
(5,761.87)	-0.03	
4,186,974.05	19.03	
662,802.00	3.01	
29,231.16	0.13	
20,797.94	0.09	

2,050,837.55	19.94
1,232.00	
(1,164.56)	-35.11
(1,360.30)	-13.92
(6,324.60)	-33.94
(18.39)	-97.10
5,761.87	100.00
341,133.15	8.15
18,256.00	2.75
1,581.28	5.41
5,900.95	28.37

		01/04/2019	12	01/04/2018	12	Variations %
	Report expressed in Euros	31/03/2020	months	31/03/2019	months	
61103014	OTHER WORKS/MISC SERVICES	24,286.58	0.09	73,066.43	0.33	(48,779.85) -66.76
61103015	General Services	52,457.51	0.22	49,101.28		3,356.23 6.84
61103024	MARKETING SUBCONTRACTING	2,445,333.81	9.04	2,082,682.57	9.47	362,651.24 ^{17.41}
61103200	DISTRIBUTION SUBCONTRACTING	1,015,941.28	3.76	518,402.78		497,538.50 95.98
61103302	STATISTICS MARKETING STUDIES	25,970.34	0.10	22,926.80		3,043.54 13.28
61320014	HG REAL ESTATE LEASING	210,473.10	0.78	206,439.75		4,033.35 1.95
61350016	Leasing Material & Furnishings B	647.70		3,773.32		(3,125.62) -82.83
61550016	Vehicle upkeep	2,718.26	0.01	610.73		2,107.53 345.08
61560017	Maintenance IT hardware	15,271.33	0.06	6,176.87		9,094.46 ^{147.23}
61560018	Maintenance software hardware	161,923.14	0.60	162,050.00		(126.86) -0.08
61611011	LIABILITY INSURANCE PREMIUM	22,485.25	0.08	18,406.94		4,078.31 22.16
61730030	QUALITY CONTROL SERVICES	336,063.85	1.24	359,140.70		(23,076.85) -6.43
61730040	PHARMACOVIGILANCE SERVICES	36,150.59	0.13	78,869.83		(42,719.24) -54.16
61810016	GENERAL DOCUMENTATION	1,604.78	0.01	5,212.72		$(3,607.94)^{-69.21}$
61850010	REGISTRATION CONFERENCES SEMINARS	89,529.86	0.33	91,255.22	0.41	(1,725.36) -1.89
62110011	TEMP STAFF HG MOI	84,952.21	0.31			84,952.21
62220012	COMMISSIONS AND	1,558,649.10	5.76	798,910.42	3.63	759,738.68 95.10
	BROKERAGES/SALE	1,000,013110		7,50,510.12		ĺ
62262010	LEGAL FEES	119,641.37	0.44	66,400.45	0.30	53,240.92 80.18
62262020	ADVERTISING FIRM FEES	40,419.48	0.15	32,664.40		7,754.60 ^{23.74}
62262030	Audit fees	104,996.48	0.39	101,281.96		3,714.52 ^{3.67}
62268014	OTHER MISCELLANEOUS FEES	154,932.86	0.57	139,181.29		15,751.57 ^{11.32}
62310010	PUBLICITY AND INSERTS	22,687.00	0.08	28,206.00		(5,519.00) -19.57
62330010	CONFERENCES AND ORGANISATION > 1			2,194.00	0.01	(2,194.00) -100.00
(2220017	DAY	01 640 05	0.30	25.675.27	0.16	45 072 60 128 87
62330017	INTERNAL SEMINARS	81,648.95	0.30	35,675.35	´ I	45,973.60 -128.87 (4,244.71) -100.00
62340013	NON-DEC. CLIENTELE GIFTS	7.5(0.42	0.03	4,244.71	0.02	(4,244.71) -700.00
62360011 62410010	ADVERTISING PRINTING TRANSPORT ON STORED PURCHASES	7,569.43 64,491.94	0.03	136,430.76	0.62	7,569.43
	OTHER TRANSPORT EXPENSES	·	0.24		´ I	(71,938.82) -52.73
62480018		12,805.26	0.03	3,849.05	´ I	8,956.21 ^{232.69}
62511010	PERSONNEL TRANSPORT EXPENSES	6,011.90	0.02	4,810.40	´ I	1,201.50 ^{24.98}
62512010	PERSONNEL TRANSPORT EXPENSES	22,932.48	0.03	6,042.00	′ I	16,890.48 279.55
62512011	TRANSPORT EXPENSES - BUS/SUBWAY TRANSPORT EXPENSES TAXIS	3,448.50	0.01	5,649.78	´ I	(2,201.28) -38.96
62512012		3,724.15 838.99	0.01	4,581.27		(2,201.28) -38.90 (857.12) -18.71
62513011 62514010	CAR RENTAL EXPENSES TRAVEL EXPENSES – EXPENSES FOR	46,541.44	0.17	5,780.03 19,929.42	· I	(4,941.04) -85.48
62515010	PERS TRAVEL EXPENSES - INDIA	40,341.44	0.17	60.10		(4,941.04) -03.40 (60.10)-100.00
62513010	EXPENSES FOR MISSIONS &	8,520.07	0.03	7,443.34		1,076.7314.47
02300010	RECEPTIONS	8,320.07	0.03	7,443.34	0.05	1,070.73
62570012	OFFICES-MISSIONS AND RECEPTIONS	1,074.59		1,034.81		39.78 3.84
62610010	POSTAGE EXPENSES	10,188.31	0.04	10,353.94		(165.63) -1.60
62620010	TELEPHONE-FAX-TELECOMMUNICAT	28,410.55	0.11	25,106.02		3,304.53 13.16
62780140	BANKING FEES-OTHER COMMISS	89,984.48	0.33	18,248.40		71,736.08 393.11
62810011	LEVIES PAID TO ORGANI	63,462.59	0.23	74,392.98		(10,930.39) -14.69
62810012	Office Cleaning Services	18,547.60	0.07	18,730.00	0.09	(182.40) -0.97
62840110	PERSON. RECRUITING EXPENSES	49,300.00	0.18	131,479.66	0.60	(82,179.66) -62.50
Taxes & equiv	alent payments	882,017.15	3.26	832,895.25	3.79	49,121.90 5.90
63310100	TRANSPORT PAYMENT		0.19		-	
		51,377.63	0.19	40,866.25	· !	10,511.38 ^{25.72}
63330300	PARTICIP. VOCATIONAL TRAINING	16,313.88	0.06	15,153.02		1,160.86 ^{7.66}
63340400 63350500	PARTICIPATION IN THE CO. EFFORT	8,711.70 2,770.19	0.03	6,630.91	· I	2,080.79 ^{31.38} (4,696.83)-62.90
	APPRENTICESHIP TAX PAYMENT	· /	0.01	7,467.02		(28,328.75) -105.89
63511012	PROFESSIONAL TAX	(1,574.75)	0.12-0.01	26,754.00	´ !	` ' '
63514000 63580018	Tax on company cars	(234.25)	0.25	704.00		(938.25) - ^{133.27} 40,347.73 ^{147.39}
	ADM. TAXES. OTHER TAXES & LEVIES	67,721.99 51.256.27	0.23	27,374.26 91,248.12	´ !	(39,991.85) -43.83
63780010 63780012	MISC. TAX TO OTHER BODIES MEDICAL AGENCY DEPOSITS	51,256.27 102,511.52	0.19	172,302.95		(69,719.43) -40.51
63780012	MEDICAL AGENCY DEPOSITS TAY ON BHADMACEUTICAL SPECIALITIES	432,123.00	1.60	1 /2,302.93	, 0.70	432,123.00
63780021	TAX ON PHARMACEUTICAL SPECIALITIES Tax on direct sales	151,039.97	0.56	444,394.72	2.02	(293,354.75) -66.01
		131,037.7/		777,334.72		
Wages and sala		1,739,257.2	4 6.43	1,629,846.03	7.41	109,411.21 ^{6.71}
64110100	SALARIES & WAGES OF BA	1,536,716.4		1,334,222.15		202,494.33 15.18
64120150	Paid TOIL	(13,323.74		(8,875.04)		(4,448.70) -50.13
64120200	Paid holidays takens	21,504.7		11,370.09		10,134.69 89.13
64120201	Change on paid holidays expenses prov.	3,107.0	2 0.01	40,926.34	0.19	(37,819.32) -92.41

port on	pressed in Euros	01/04/2019 31/03/2020	12 months	01/04/2018 31/03/2019	12 months	Variations	%
64120231	Change CET prov.	373.15	montas	6,006.55	0.03	(5,633.40)	-93.79
64120240	TOIL to be taken /TOIL not	3,777.64	0.01	78.49	0.03	3,699.15	N/S
64120250	Insecurity bonus	1,095.16	0.01	2,190.72	0.01	(1,095.56)	-50.01
64130300	NETWORK BONUS	2,917.20	0.01	6,561.00	0.03	(1,095.56)	-55.54
64130420	Bonus.	144,656.73	0.53	200,575.99	0.91	(55,919.26)	-27.88
64140380	Severance pay	23,630.50	0.09	18,622.02	0.08	5,008.48	26.90
64140500	Benefits in kind	8,225.00	0.03	12,389.48	0.06	(4,164.48)	-33.61
64190220	Transportation benefits	6,577.32	0.02	5,778.24	0.03	799.08	13.83
Dorsonnal	social abaygos	808,609.03	2.99	692,403.89	3.15	116,205.14	16.78
64510100	social charges URSSAF LEVIES.	454,534.76	1.68	397,786.41	1.81	56,748.35	14.27
64530120	PRO. FUNDS LEVIES	16,092.65	0.06	15,522.49	0.07	570.16	3.67
64530130	PENSION FUNDS LEVIES	188,249.48	0.70	148,337.68	0.67	39,911.80	26.91
64540140	ASSEDIC/APEC. LEVIES.	68,903.26	0.25	54,846.45	0.25	14,056.81	25.63
64580170	OTHER LEVIES	15,442.56	0.06	18,642.90	0.08	(3,200.34)	-17.17
64590000	CICE	15,442.50	0.00	(13,621.00)	-0.06	13,621.00	100.00
64590001	Change social ch. on prov	1,453.31	0.01	20,463.15	0.09	(19,009.84)	-92.90
64590002	Change social ch. on other	2,622.98	0.01	4,404.55	0.02	(1,781.57)	-40.45
64720200	OPERATING SUBSIDY C	2,668.53	0.01	2,946.92	0.01	(278.39)	-9.45
64740310	OTHER SOCIAL WORKS	16,489.32	0.06	13,261.40	0.06	3,227.92	24.34
64750400	Occupational healthcare	4,644.86	0.02	586.43	0.00	4,058.43	692.06
64800000	Other personnel expenses	18,582.32	0.07	17,393.43	0.08	1,188.89	6.84
64810010	PROFESSIONAL	18,925.00	0.07	11,833.08	0.05	7,091.92	59.93
0.1010010	DEVELOPMENT	10,725100	0.07	11,055.00	0.05	7,001102	07.70
Amortisatio	on expenses on fixed assets	52 040 05	0.20	74.564.00	0.24	(20.715.05)	27.70
		53,848.95		74,564.00	0.34	(20,715.05)	-27.78
68111300	TRADEMARKS AMORT alloc	9,312.00	0.03	37,797.0	0.17	(28,485.00)	-75.36
68112510	TANGIBLE FIXED ASSETS DEPREC ALLOC - AU	44,536.95	0.16	36,767.0	0 0.17	7,769.95	21.13
				,			
Provisions 6	expense on liquid assets	2,268,384.75	8.39	884,640.87	4.02	1,383,743.88	156.42
68173000	Alloc. To provisions for	1,939,649.57	7.17	725,892.	73 3.30	1,213,756.84	167.21
1	depre		7.27		3.30		107.21
68174000	Allocations to provisions for	328,735.18	1.22	158,748.	14 0.72	169,987.04	107.08
Allocations	to prov. for contingencies	125,796.00	0.47	153,052.54	0.70	(27,256.54)	-17.81
and loses	1	123,790.00	0.47	155,052.54	0.70	(27,230.34)	-1/.01
68150000	Allocation to provisions for	86,416.00	0.32	123,000.0	0 0.56	(36,584.00)	-29.74
l	???		0.15				
68150001	Allocations social R&C provisions	39,380.00	0.15	30,052.5	4 0.14	9,327.46	31.04
	to-day management expenses	58,375.46	0.22	135,205.25	0.61	(76,829.79)	-56.82
5112000	Non-Group royalties for co			18,878.2	8 0.09	(18,878.28)	-100.00
65400000	Loss on irrecov. Debts	35,896.89	0.13	109,621.2	7 0.50	(73,724.38)	-67.25
65800000	CO. MGMT	22,478.57	0.08	6,705.7	0 0.03	15,772.87	235.22
3200000		,		-,,,	0.05	12,7,7=10,7	233.22
3300000	MISCELLANEOUS						
3330000	MISCELLANEOUS EXPENSES						
Operating i	EXPENSES	(3,228,687.89)	-11.94	(4,401,616.8)	-20.01	1,172,928.92	26.65
Operating i	EXPENSES ncome	(3,228,687.89)	-11.94		3.24	1,172,928.92	26.65 N/S
Operating i	expenses ncome cial products	1,245.03	-11.94	73	3.24	1,171.79	N/S
Operating i Total finance Translation	expenses ncome cial products gains	1,245.03 1,245.03	-11.94	73.24	3,24	1,171.79	
Operating i	expenses ncome cial products	1,245.03	-11.94	73	3,24	1,171.79	N/S
Operating i Total finance Translation 76600000	expenses ncome cial products gains	1,245.03 1,245.03	-11.94	73.24	3.24	1,171.79 1,171.79 1,171.79	N/S N/S
Operating i Total finance Translation 76600000 Total finance	expenses ncome cial products gains Gain de change/Revaluation cial products	1,245.03 1,245.03 1,245.03 532,365.36	1.97	73.24 73.24 73.2 533,06	3.24 4 9.33 2.42	1,171.79 1,171.79 1,171.79 (703.97)	N/S N/S N/S -0.13
Operating i Total finance Translation 76600000 Total finance Interests an	EXPENSES ncome cial products gains Gain de change/Revaluation cial products d similar expenses	1,245.03 1,245.03 1,245.03 532,365.36 531,433.03	1.97	73.24 73.24 73.2 533,06	3.24 4 9.33 2.42	1,171.79 1,171.79 1,171.79 (703.97) 4,266.72	N/S N/S N/S -0.13
Operating i Total finance Translation 76600000 Total finance	EXPENSES ncome cial products gains Gain de change/Revaluation cial products d similar expenses BANK INTEREST ON	1,245.03 1,245.03 1,245.03 532,365.36	1.97	73.24 73.24 73.2 533,06	3.24 4 9.33 2.42 2.40	1,171.79 1,171.79 1,171.79 (703.97) 4,266.72	N/S N/S N/S -0.13
Operating i Total finance Translation 76600000 Total finance Interests an 66160200	EXPENSES ncome cial products gains Gain de change/Revaluation cial products d similar expenses BANK INTEREST ON OPERATI	1,245.03 1,245.03 1,245.03 532,365.36 531,433.03 404,799.05	1.97 1.97 1.50	73.24 73.24 73.2 533,06 527,166.31 437,543.3	3.24 4 9.33 2.42 5 1.99	1,171.79 1,171.79 1,171.79 (703.97) 4,266.72 (32,744.30)	N/S N/S N/S -0.13 0.81 -7.48
Operating i Total finance Translation 76600000 Total finance Interests an	EXPENSES ncome cial products gains Gain de change/Revaluation cial products d similar expenses BANK INTEREST ON	1,245.03 1,245.03 1,245.03 532,365.36 531,433.03	1.97	73.24 73.24 73.2 533,06	3.24 4 9.33 2.42 5 1.99	1,171.79 1,171.79 1,171.79 (703.97) 4,266.72 (32,744.30)	N/S N/S N/S -0.13
Operating i Total finance Translation 76600000 Total finance Interests an 66160200 66500100	EXPENSES Income Cial products Gains Gain de change/Revaluation Cial products Id similar expenses BANK INTEREST ON OPERATI DISCOUNTS GRANTED HG	1,245.03 1,245.03 1,245.03 1,245.03 532,365.36 531,433.03 404,799.05 126,633.98	1.97 1.97 1.50	73.24 73.24 73.2 533,06 527,166.31 437,543.3 89,622.9	3.24 4 9.33 2.42 2.40 5 1.99 6 0.41	1,171.79 1,171.79 1,171.79 (703.97) 4,266.72 (32,744.30) 37,011.02	N/S N/S N/S -0.13 0.81 -7.48 41.30
Operating i Total finance Translation 76600000 Total finance Interests an 66160200 66500100	EXPENSES cial products gains Gain de change/Revaluation cial products d similar expenses BANK INTEREST ON OPERATI DISCOUNTS GRANTED	1,245.03 1,245.03 1,245.03 532,365.36 531,433.03 404,799.05	1.97 1.97 1.50	73.24 73.24 73.2 533,06 527,166.31 437,543.3	3.24 4 9.33 2.42 2.40 5 1.99 6 0.41	1,171.79 1,171.79 1,171.79 (703.97) 4,266.72 (32,744.30) 37,011.02 (4,970.69)	N/S N/S N/S -0.13 0.81 -7.48

14

Report expressed in Euros	01/04/2019 31/03/2020	12 months	01/04/2018 12 months 31/03/2019	Variations	%
Financial results financier	(531,120.33)	-1.96	(532,996.09) -2.42	1,875.76	0.35
Pre-tax earnings	(3,759,808.22)	-13.90	(4,934,612.90) -22.43	1,174,804.68	23.81
Total non-recurring income	796,867.52	2.95	224,441.60 1.02	572,425.92	255.04
Extraordinary charges on capital operation 77200000 Revenue from previous years	796,867.52 796,867.52	2.95 2.92	224,441.60 1.02 224,441.60 1.02	572,425.92 572,425.92	255.04 255.04
Total non-recurring expenses	28,392.82	0.10	350.43	28,042.39	N/S
Extraordinary charges on management operation 67121000 Supplier increases 67200000 Expenses on previous fiscal years	28,392.82 20.33 28,372.49	0.10	350.43 350.43	28,042.39 (330.10) 28,372.49	N/S -94.20
Extraordinary results	768,474.70	2.84	224,091.17	544,383.53	242.92
Financial year results	(2,991,333.52)	-11.06	(4,710,521.73) -21.41	1,719,188.21	36.50

15

Financial statements as at 31/03/2020

APPENDICES

APPENDIX - Note 1

Accounting Rules and Methods

Statement expressed in Euros

The financial statements for the year have been prepared and presented in accordance with the applicable general rules and in compliance with the principle of prudence.

The balance sheet for the financial year shows a total of €13,551,356.

The income statement, presented in the form of a list, shows:

Total income of $\in 28,914,104$ Total expenses of $\in 31,905,438$, Thus, generating a loss of $\in -2,991,334$.

The financial year under consideration covers the period 01/04/2019 to 31/03/2020, i.e. 12 months versus 12 months the prior financial year.

The following notes and tables form an integral part of the annual financial statements.

General accounting policies have been applied in compliance with the basic assumptions of:

- going concern principle
- consistency of accounting methods over the financial years
- appropriate cut-offs

And in compliance with the applicable French regulations arising from the decrees of the Regulatory Committee.

The basic method used for the valuation of items recorded in the accounts is the historical cost method.

Tangible assets

Tangible assets are valued at their acquisition cost (purchase price plus incidentals excluding expenses for the acquisition of the fixed assets) or at their production cost. The company has decided to recognise fixed assets acquisition expenses as charges.

Depreciation is based on the useful life.

Computer equipment: Declining balance method over 3 years

Fittings: Straight line method over 10 years Furniture: Straight line method over 10 years

Other equipment: Declining balance method over 5 years

16

17

APPENDIX - Note 1

Accounting Rules and Methods

Statement expressed in Euros

Intangible assets

Intangible assets are valued at their acquisition cost (purchase price and incidentals, excluding expenses for the acquisition of the fixed assets).

They consist of items acquired and relate to licences, patents and MA dossiers.

MA files are amortised over a period of five years on a straight line basis.

Other amortisations are based on the useful life.

When the inventory value is lower than the gross value, a provision for depreciation, equal to the difference, is recognised.

Investments in associates

Financial investments represent participating shares in OPIH for a value of €4,372,238.

These shares are included in assets at their acquisition cost of €1,000,000.

The discrepancy between the value of the securities and the net situation was covered by a provision of €3,372,238.

In fact, on the one hand, OPIH has cash facilities (including current account over our company) of €2.6m and, on the other hand, the value in use of the company's shares which lies in the medical and marketing know-how of the network of medical representatives it employs is deemed to be higher than the book value.

In addition, on 26 February 2020, the Company, the sole shareholder of OPIH, decided to dissolve said company without liquidation in accordance with the provisions of Article 1844-5 paragraph 3 of the French Civil Code, effective for accounting purposes 30 days after the publication on 24 March 2020, i.e. on 23 April 2020, and effective for tax purposes on 1 April 2020.

Stocks

Stocks are valued using the weighted average price method.

The gross value of goods and supplies includes the purchase cost plus incidentals.

A provision for depreciation of stock, equal to the difference between the gross value based on the method specified above and the market value, is recognised when the gross value is higher than the market value. The impairment test is based on product turnover and the expiry date.

18

APPENDIX - Note 1

Accounting Rules and Methods

Report expressed in Euros

Receivables

Receivables are recognised at their nominal value.

A provision for depreciation is recognised when a loss is likely.

The depreciation methods for trade receivables are as follows:

- 100% if aged more than 90 days.
- 50% if aged more than 60 days.

Provisions for risks and charges

Risks and charges, the nature of which is clearly specified, that become likely on account of past or current events give rise to the recognition of a provision.

On the reporting date, the provision for litigation with personnel amounts to €198 K.

In accordance with the prospective method for retirement commitments, the company recognises a provision covering commitments relating to employee rights in its accounts, pursuant to the collective agreement of the pharmaceutical industry, at the time of retirement. The provision for retirement benefits is estimated individually for each employee present on 31/03/2020 and who has at least one year of seniority, while considering the following parameters:

- -the applicable collective bargaining agreement
- -the employee's probable salary upon retirement, based on career development assumptions specific to the company

The provisioned amount is determined using an actuarial method, as it includes the following parameters:

- -the amount of the benefit to be paid
- -the probability of being a company employee at the time of retirement, given the turnover within the company and the average mortality per age and per sex defined by the INSEE
- -a discounting rate of 1.50%.

The provision for retirement commitments amounts to €290 K.

19 Page: SUN PHARMA FRANCE

APPENDIX - Note 1

Accounting Rules and Methods

Statement expressed in Euros

Capital and Reserves

The share capital amounts to €24,948,400 made up of 24,948,400 shares of a nominal value of €1 each. It is fully paid up.

Pursuant to the decision of the shareholders at the General Meeting of 25 May 2019, the loss recognised in the accounts as at 31 March 2019 has been carried forward for an amount of -€4,710,522.

Capital and Reserves on 31 March 2019: - €32,040,186 Result of the financial year: -€2,991,334 Capital and Reserves on 31 March 2020: -€35,031,519

With continuing negative shareholders equity after the losses recorded during the financial years ending on 31 March 2018, 31 March 2019 and 31 March 2020, the partner heading up the company's group, the Sun Pharmaceutical Ltd group, has confirmed its financial support for the company till 31 March 2020.

Tax consolidation

Since 01/01/2006, and tacitly renewed since 01/01/2011, SUN PHARMA FRANCE has opted for tax consolidation. The earnings of its subsidiary OPIH are consolidated into that of SUN PHARMA FRANCE, the only entity liable to corporation tax, additional taxes and the minimum annual corporation tax payable by the Group.

The taxable result notified to the company by its subsidiary OPIH for the 2019-2020 financial period shows a tax deficit of €144,492.

Change of valuation method

There was no change to the valuation method during the financial year.

Change of presentation method

There was no change to the presentation method during the financial year.

20

APPENDIX - Note 1

Accounting Rules and Methods

Statement expressed in Euros

Significant events

The group has confirmed its financial support to the company till 31 March 2021, thus justifying the going concern assumption made for the closing of the accounts.

Like other actors in the distribution sector for medicinal products in France, the company has been the subject of an inquiry by the DGCCRF regarding the sale price of medicinal products and its commercial policy from 2013. Up to now, the notifications in progress from the DIRECCTE relative to marketing expenses have not been the subject of any complaints.

Post-closing events

On 26 February 2020, SUN PHARMA France, the sole shareholder of OPIH, decided to dissolve OPIH without liquidation in accordance with the provisions of Article 1844-5 paragraph 3 of the French Civil Code, effective for accounting purposes 30 days after the publication on 24 March 2020, i.e. on 23 April 2020, and effective for tax purposes on 1 April 2020.

Additional information

On 4 December 2019, the Company's name was changed from RANBAXY PHARMACIE GENERIQUES to SUN PHARMA FRANCE.

The fees paid to the statutory auditors to certify the company's financial statements amount to €56K.

Extraordinary Income

Extraordinary income was €797 K and consists of adjustments to third party accounts. (Text to be translated/updated)

<u>Information concerning the impact of the Covid-19 epidemic on the company's business</u> after the balance-sheet date

The company reports that the Covid-19 health crisis and the declaration of a health state of emergency will have a significant impact on its business.

In light of how rapidly the situation changes, it is difficult to estimate the financial impacts. As at the reporting date, the company is not yet able to calculate the exact impact of the crisis on its assets and liabilities, financial situation and profit/loss.

21

APPENDIX - Note 2

Fixed assets

	Γ	Opening			Gross value as		
statement expressed in Euros		values	Increa	ise	Decrea	se	at 31/03/2019
			Revaluations	Acquisitions	Re-classifications	Disposals	
E-J	Preliminary and development costs						
BLI	reminiary and development costs						
NGI	Others	12,251,753					12,251,75
INTANGIBLE	TOTAL INTANGIBLE ASSETS	12,251,753					12,251,75
					1		·
	Lands						
	Buildings on freehold land On leasehold land Fixtures, fittings, installations						
	Technical instal., industrial equipment and tools						
LE	Sundry fixtures, fittings, installations Transport equipment	19,577					10.55
TANGIBLE	Office equipment, furniture	259,671		10,215			19,57 269,88
ANG	Recyclable and other packaging						
T	Tangible assets in progress						
	Advances and prepayments						
	TO TAL TANGIBLE ASSETS	279,249		10,215			289,464
			1	1			Г
	Investments in associates valued by the equity method						
ΑL	Other equity interests	4,372,238					4,372,23
\CL	Other fixed investments						
FINANCIAL	Loans and other financial assets	108,496					108,49
FI	TOTAL FINANCIAL ASSETS	4,480,734					4,480,73
	TOTAL	17,011,735		10,215			17,021,950

APPENDIX - Note 3

Depreciation and Amortisation

		Opening amortization	Movements d	luring the year	Amortisation as at 31/03/2019
State	ment expressed in Euros	amoruzation	Provisions	Reversals	ut 01/00/2019
INTANGIBLE	Preliminary and development costs Others	11,779,386	17,207		11,796,592
INTAI	TOTAL INTANGIBLE ASSETS	11,779,386	17,207		11,796,592
TANGIBLE	Lands Buildings on freehold land On leasehold land Fixtures, fittings, installations Technical instal., industrial equipment and tools Sundry fixtures, fittings, installations Transport equipment Office equipment, furniture Recyclable and other packaging	113,689	36,642		150,332
	TOTAL TANGIBLE ASSETS	113,689	36,642		150,332
	TOTAL	11,893,075	53,849		11,946,924

Ī		Provision	ıs	Reversals			Change in depreciation and
	Duration and other differential	Diminishing balance mode	Exceptional tax amort.	Duration and other differential	Diminishing balance mode	Exceptional tax amort.	amortization an year-end
Preliminary and development costs							
Other tangible assets							
TOTAL INTANGIBLE ASSETS							
Lands							
Buildings on freehold land							
On leasehold land							
Fixtures, fittings, installations							
Technical instal., industrial equipment and tools							
Sundry fixtures, fittings, installations							
Transport equipment							
Office equipment, IT, furniture							
Recyclable and other packaging							
TOTAL TANGIBLE ASSETS							
Cost of acquisition of participating shares							
TOTAL							
GRAND TOTAL NOT BROKEN DOWN							

Page:

23

APPENDIX - Note 4

Provisions

tatemer	nt expressed in Euro	os	Opening	Increase	Decrease	31/03/2019
	Reconstruction mi	ning and oil deposits				
SN	Provisions for inve	estment				
ISIO	Provisions for pric	e increases				
ROV	Provision for accel	lerated depreciation				
ED P	Tax provision for i	installation loans				
REGULATED PROVISIONS	Other provisions					
REGI	REGULATED PI	ROVISIONS				
PROVISIONS FOR RISKS AND CHARGES	For litigation For guarantees giv For losses on futur For fines and pena	es markets	123,000	75,416		198,416
IONS FOR CHARGES	For exchange lossor For pensions and s For taxes	es similar obligations	250,835	39,380		290,215
PROVIS	For renewals of fix Provisions for maj renovations For social security					
	accrued leaves Other	S		11,000		11,000
	PROVISIONS FO	OR RISKS AND CHARGES	373,835	125,796		499,631
2 -	Д	intangible tangible shares valued by the equity method	446,818			446,818
ONS FOR IATION	On fixed assets -	Participating shares Other financial assets	3,372,238 68,385			3,372,238 68,385
PROVISIO DEPRECI	On stocks and wor On trade debtors Others	k in progress	732,905 347,572	1,939,650 328,735	725,893 347,572	1,946,662 328,735
	PROVISIONS PO	OUR DEPRECIATION	4 967,918	2,268,385	1,073,465	6,162,838
		GRAND TOTAL	5 241 552	2 204 101	1.072.465	6,662,469
			5,341,753	2,394,181	1,073,465	0,002,409
O	f which provisions a	- operating - financial - extraord		2,394,181	1,073,465	
	es accounted for by tided for in Article 39	the equity method: depreciation a 0-1.5e of the GTC	mount at the year-end c	alculated in accordance	e with the rules	

Page:

24

APPENDIX - Note 5

Receivables and Payables

	Statement expressed in Euros	31/03/2020	<= 1 year	> 1 year
RECEIVABLES	Receivables from associates Loans (1) (2) Other financial assets Bad and Doubtful debts Other trade receivables Receivables representing loaned securities Personnel and related accounts Social Security and other social bodies Tax on profits Value added tax Other taxes, duties and similar payments Miscellaneous Group and associates (2) Sundry debtors Prepaid expenses	68,385 40,111 336,397 5,149,158 15,156 59,497 612,503 39,664 4,461 363,376	5,149,158 15,156 59,497 612,503 39,664 4,461 363,376	68,385 40,111 336,397
	TOTAL RECEIVABLES	6,688,707	6,243,815	444,893
(1) (1) (2)	Repayments obtained during the year			

	L	31/03/2019	<= 1 year	1 - 5 years	> 5 years
	Convertible debenture loans (1)				
	Other debenture loans (1) Loans/debts from credit instit at less than 1 year	16.502	16,592		
	from start (1)	16,592	10,392		
	Loans/debts from credit instit at more than 1 year from start (1)				
	Loans and miscellaneous financial debts (1) (2)	33,602,061	33,602,061		
	Trade payables and related accounts	11,501,681	11,501,681		
	Personnel and related accounts	455,792	455,792		
PAYABLES	Social Security and other social bodies	257,255	257,255		
ABI	Tax on profits				
AY.	Value added tax	101,673	101,673		
Ъ	Guaranteed bonds				
	Other taxes, duties and similar payments	1,126,796	1,126,796		
	Debts on fixed assets and related accounts				
	Group and associates (2)	1,554,500	1,554,500		
	Other payables	6,895	6,895		
	Debt representing borrowed securities				
	Prepaid income				
	TOTAL PAYABLES	48,083,245	48,083,245		
(1)	T (1) (1		·		
(1)	ē ;				
(1)					
(2)	Loans and devis from associates (natural persons)				

Page:

25

APPENDIX - Note 6.10

ACCRUED INCOME

	Statement expressed in	Euros	31/03/2020
Total Income receivable			175,388
Other trade receivables TRADE RECEIVABLES, UNBILLED REVENUE		129,694	129,694
Other claims OCCUPATIONAL TRAINING STATE-INCOME RECEIVABLE		6,030 39,664	45,694

26

APPENDIX - Note 6.11

Accrued expenses

Statement expressed in Euros

31/03/2020

Total accrued expenses		
Loans and debts from credit institutions		4.
ACCRUED INTERESTS PAYABLE	4,000	
Other loans and financial debts		959.
INTEREST GROUP LOANS	959,876	
Trade payables and related accounts		1,181
UNDELIVERED INVOICE cpt Entry m	565,783	
SUPPLIER, UNDELIVERED INVOICES	615,218	
Tax and social security liabilities		566
PROVISIONS FOR ACCRUED TOIL	11,475	
PROVISIONS ACCRUED LEAVE	45,663	
PROVISIONS FOR ACCRUED LEAVE	120,638	
PROVISIONS FOR TIME SAVINGS ACCOUNT	14,070	
PERSONNEL, ACCRUED EXPENSES	256,772	
PROVISIONS FOR ACCRUED SOCIAL CHARGES	16,454	
SOCIAL INSTITUTIONS, ACCRUED EXPENSES	83,271	
SOCIAL INSTITUTIONS, ACCRUED EXPENSES	7,035	
EFFORT CONSTRUCTION	8,182	
PROFESSIONAL TRAINING	2,770	
Other liabilities		6
CUSTOMER CREDIT NOTES NOT YET ISSUED	6,895	

27

APPENDIX – Note 6.12

Prepayments

Statement expressed in Euros	Period	Amounts	31/03/2020
Prepayments - OPERATING			363,376
Other charges accounted for in advance		363,376	
Prepayments - FINANCIAL			
Prepayments - EXTRAORDINARY			
Tra	OTAL		363,376
	OTAL		303,370

28

APPENDIX - Note 6.12

Prepaid income

Statement expressed in Euros	Period	Amounts	31/03/2020
Prepaid income – OPERATING			
Advances on contracts			
NONE			
Prepayments - FINANCIAL			
Prepayments - EXTRAORDINARY			
TO	OTAL		

SOGECC		SUN PHARMA FRANCE		Page:	29	
--------	--	-------------------	--	-------	----	--

APPENDIX - Note 6.14

Issue Capital

	Statement expressed in Euros 31/03/2020	Number	Par value	Amount
SATE RIGHTS	Of the issued capital at start of financial year Issued during the financial year	24,948,400.00	1,0000 0,0000	24,948,400.00
SHARES/CORPORATE RIGHTS	Reimbursed during the financial year Of the issued capital at end of financial year	24,948,400.00	0,0000 1,0000	24,948,400.00

30

APPENDIX - Note 6.17

Breakdown of turnover

	Statement expressed in Euros	31/03/2020
Turnover by business line		27,042,241
Sales of goods		25,848,830
SALES OF GOODS FRANCE HG DISCOUNTS GRANTED	33,075,489 (7,226,659)	
Production sold Services		1,193,412
MISCELLANEOUS SERVICES FRANCE HG OTHER EXPORT SERVICES	21,885 1,167,055	
INCOME FROM RELATED ACTIVITIES	4,471	
Turnover by geographical market		27,042,24
FRANCE turnover		25,875,186
SALE OF GOODS FRANCE HG	33,075,489	
REBATES/DISCOUNTS/ALLOWANCES GRANTED	(7,226,659)	
MISCELLANEOUS SERVICES FRANCE H INCOME FROM RELATED ACTIVITIES	21,885	
	4,471	
EXPORT Turnover		1,167,05
OTHER EXPORT SERVICES	1,167,055	

SOGECC

SUN PHARMA FRANCE

Page:

1

APPENDIX – Note 6.18

Breakdown of tax on profits

			_
ITIES	(3,759,808)		(3,759,808
iterests)	768,475		768,47
	(2,991,334)		(2,991,334
	ITIES nterests)	nterests) 768,475	nterests) 768,475

32

APPENDIX - Note 11

Increase and decrease in future tax liabilities

Sta	atemen	at expressed in Euros	31/03/2020
	INCREASE	Regulated provisions Other	
		INCREASE IN FUTURE TAX LIABILITIES	
		Provisions not deductible in the year of recognition Provisions for retirement benefits Provisions for doubtful debts Provisions for MA (31/12/2012) Provisions for loan for building initiative	72,554 82,184 66,633 17,096
	DECREASE	Other Provisions for accrued leaves Social housing level Effort construction (Tax loss carry-forwards??)	45,239 14,714,391 2,178
		DECREASE IN FUTURE TAX LIABILITIES	15,000,275

The amounts indicated in the above table are expressed in taxes.

go.	OT.	00	
>()(1214	CC	

Page:

33

APPENDIX - Note 12

Directors' remuneration

Statement expressed in Euros	31/03/2020
Remuneration of members:	
- Of administration bodies	
- Of management bodies	
- Of supervisory bodies	
	La Alexa Parallea and C
n compliance with the principle of respect for people's rights, this information is not provided since it would indirectly lead t nformation of a personal nature.	the disclosure of

Page:

34

APPENDIX - Note 13

Average headcount

		31/03/2020	Internal	External
ORY				
ATEG	Managers & intellectual professions		15	
PER C	Intermediate professions		4	
COUNT	White collar employees		1	
AVERAGE HEADCOUNT PER CATEGORY	Blue collar employees			
RAGE	TOTAL		20	
AVE				

Parent companies consolidating the financial statements

Sun Pharma Frai	nce is a company included in the consolidation of Sun Pharmaceutical Industries Ltd, which publishes its consolidated
inancial stateme	ents in accordance with the Indian GAAP standards.
The French sub-	group meets the conditions for exemption from the preparation of consolidated financial statements due to its size.

36

APPENDIX - Note 15

Subsidiaries and associates

31/03/2020	Capital and reserves	Quota Percentage shareholding	Earnings of the last financial year ended
	1,291,858	100.00	18,232
	31/03/2020	31/03/2020 reserves	31/03/2020 Percentage shareholding

SOGECC SUN PHARMA FRANCE

TAX FORMS TO 31/03/2020 Page:

38